Literature DB >> 25573462

Characteristics and outcomes of human parechovirus infection in infants (2008-2012).

Stefania Vergnano1, Seilesh Kadambari, Katrina Whalley, Esse N Menson, Nuria Martinez-Alier, Mehrengise Cooper, Emile Sanchez, Paul T Heath, Hermione Lyall.   

Abstract

UNLABELLED: Human parechoviruses (HPeVs) cause a spectrum of disease ranging from self-limiting illness to severe disease and, sometimes, death. We describe the clinical characteristics and outcomes of HPeV infection in infants. The study describes the clinical and laboratory characteristics and outcomes of infants with HPeV infection during 2008-2012, from three paediatric hospitals in London each with a paediatric intensive care unit. The infants were retrospectively identified through laboratory and patient discharge databases and diagnosed through HPeV PCR. Fifty infants were identified. Half required admission to PICU. Infants less than 3 months were more likely to require PICU (16/25: p < 0.01). Clinical signs at presentation were often indistinguishable from those of bacterial sepsis and meningitis, but inflammatory markers were nearly always (95 % of cases) within normal ranges. Brain MRI showed white matter changes in 10/12 infants. Three of 19 infants with follow-up data (16 %) had significant neurological sequelae.
CONCLUSION: HPeV may cause severe disease and long-term neurological sequelae in young infants. HPeV should be considered in infants with clinical features of sepsis/meningitis with normal CSF microscopy. Prospective observational studies are warranted to better define the epidemiology of infection and thus inform future treatment trials.

Entities:  

Mesh:

Year:  2015        PMID: 25573462     DOI: 10.1007/s00431-014-2483-3

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.860


  20 in total

1.  Molecular epidemiology and genetic diversity of echovirus type 30 (E30): genotypes correlate with temporal dynamics of E30 isolation.

Authors:  M S Oberste; K Maher; M L Kennett; J J Campbell; M S Carpenter; D Schnurr; M A Pallansch
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

2.  Comparison of human parechovirus and enterovirus detection frequencies in cerebrospinal fluid samples collected over a 5-year period in edinburgh: HPeV type 3 identified as the most common picornavirus type.

Authors:  Heli Harvala; Nigel McLeish; Jasmina Kondracka; Chloe L McIntyre; E Carol McWilliam Leitch; Kate Templeton; Peter Simmonds
Journal:  J Med Virol       Date:  2011-05       Impact factor: 2.327

3.  Detection of human enterovirus and human parechovirus (HPeV) genotypes from clinical stool samples: polymerase chain reaction and direct molecular typing, culture characteristics, and serotyping.

Authors:  Kimberley Benschop; Rene Minnaar; Gerrit Koen; Hetty van Eijk; Karen Dijkman; Brenda Westerhuis; Richard Molenkamp; Katja Wolthers
Journal:  Diagn Microbiol Infect Dis       Date:  2010-10       Impact factor: 2.803

4.  Impact of diagnostic procedures on patient management and hospitalization cost during the 2000 and 2005 enterovirus epidemics in Marseilles, France.

Authors:  L Ninove; C Tan; A Nougairede; C Zandotti; H Richet; R Charrel; X de Lamballerie
Journal:  Clin Microbiol Infect       Date:  2009-12-10       Impact factor: 8.067

5.  Human parechovirus causes encephalitis with white matter injury in neonates.

Authors:  Malgorzata A Verboon-Maciolek; Floris Groenendaal; Cecil D Hahn; Jonathan Hellmann; Anton M van Loon; Guy Boivin; Linda S de Vries
Journal:  Ann Neurol       Date:  2008-09       Impact factor: 10.422

6.  Specific association of human parechovirus type 3 with sepsis and fever in young infants, as identified by direct typing of cerebrospinal fluid samples.

Authors:  H Harvala; I Robertson; T Chieochansin; E C McWilliam Leitch; K Templeton; P Simmonds
Journal:  J Infect Dis       Date:  2009-06-15       Impact factor: 5.226

7.  Impact of rapid polymerase chain reaction results on management of pediatric patients with enteroviral meningitis.

Authors:  Christine C Robinson; Mary Willis; Ashley Meagher; Karen E Gieseker; Harley Rotbart; Mary P Glodé
Journal:  Pediatr Infect Dis J       Date:  2002-04       Impact factor: 2.129

8.  Prevalence of human parechovirus in the Netherlands in 2000 to 2007.

Authors:  Sabine van der Sanden; Erwin de Bruin; Harry Vennema; Caroline Swanink; Marion Koopmans; Harrie van der Avoort
Journal:  J Clin Microbiol       Date:  2008-07-09       Impact factor: 5.948

9.  Human parechoviruses as an important viral cause of sepsislike illness and meningitis in young children.

Authors:  Katja C Wolthers; Kimberley S M Benschop; Janke Schinkel; Richard Molenkamp; Rosemarijn M Bergevoet; Ingrid J B Spijkerman; H Carlijn Kraakman; Dasja Pajkrt
Journal:  Clin Infect Dis       Date:  2008-08-01       Impact factor: 9.079

10.  Prospective comparison of the detection rates of human enterovirus and parechovirus RT-qPCR and viral culture in different pediatric specimens.

Authors:  S C M de Crom; C C Obihara; R A de Moor; E J M Veldkamp; A M van Furth; J W A Rossen
Journal:  J Clin Virol       Date:  2013-08-21       Impact factor: 3.168

View more
  13 in total

Review 1.  Human Parechovirus: an Increasingly Recognized Cause of Sepsis-Like Illness in Young Infants.

Authors:  Laudi Olijve; Lance Jennings; Tony Walls
Journal:  Clin Microbiol Rev       Date:  2017-11-15       Impact factor: 26.132

2.  A 2.8-Angstrom-Resolution Cryo-Electron Microscopy Structure of Human Parechovirus 3 in Complex with Fab from a Neutralizing Antibody.

Authors:  Aušra Domanska; Justin W Flatt; Joonas J J Jukonen; James A Geraets; Sarah J Butcher
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

Review 3.  Encephalitis in US Children.

Authors:  Kevin Messacar; Marc Fischer; Samuel R Dominguez; Kenneth L Tyler; Mark J Abzug
Journal:  Infect Dis Clin North Am       Date:  2017-12-08       Impact factor: 5.982

4.  Human Parechovirus Meningoencephalitis: Neuroimaging in the Era of Polymerase Chain Reaction-Based Testing.

Authors:  A Sarma; E Hanzlik; R Krishnasarma; L Pagano; S Pruthi
Journal:  AJNR Am J Neuroradiol       Date:  2019-07-04       Impact factor: 3.825

5.  Severe Parechovirus 3 Infections in Young Infants-Kansas and Missouri, 2014.

Authors:  Claire M Midgley; Mary Anne Jackson; Rangaraj Selvarangan; Patrick Franklin; Elizabeth L Holzschuh; Jennifer Lloyd; Joseph Scaletta; Anne Straily; Sheri Tubach; Ashley Willingham; W Allan Nix; M Steven Oberste; Christopher J Harrison; Charles Hunt; George Turabelidze; Susan I Gerber; John T Watson
Journal:  J Pediatric Infect Dis Soc       Date:  2018-05-15       Impact factor: 3.164

6.  Outcome of routine cerebrospinal fluid screening for enterovirus and human parechovirus infection among infants with sepsis-like illness or meningitis in Cornwall, UK.

Authors:  Prithwiraj Chakrabarti; Chris Warren; Laura Vincent; Yadlapalli Kumar
Journal:  Eur J Pediatr       Date:  2018-07-18       Impact factor: 3.860

7.  Human parechovirus meningitis and gross-motor neurodevelopment in young children.

Authors:  Ted M T van Hinsbergh; Stephanie C M de Crom; Robert Lindeboom; Marceline A M van Furth; Charlie C Obihara
Journal:  Eur J Pediatr       Date:  2019-01-14       Impact factor: 3.860

Review 8.  The mouse cortical meninges are the site of immune responses to many different pathogens, and are accessible to intravital imaging.

Authors:  Jonathan A Coles; Phillip J Stewart-Hutchinson; Elmarie Myburgh; James M Brewer
Journal:  Methods       Date:  2017-03-27       Impact factor: 3.608

9.  Infant identical triplets' presentation of human parechovirus Type 3.

Authors:  Bryan Weichelt; Elisabeth Hooper; Brian Chow
Journal:  IDCases       Date:  2019-01-24

10.  Evolutionary analysis of human parechovirus type 3 and clinical outcomes of infection during the 2017-18 Australian epidemic.

Authors:  Anthony Chamings; Julian Druce; Leon Caly; Yano Yoga; Philip N Britton; Kristine K Macartney; Soren Alexandersen
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.